ロード中...
Effectiveness of EGFR‐TKIs in a Patient with Lung Adenocarcinoma Harboring an EGFR‐RAD51 Fusion
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR‐TKIs) have become the first choice for patients with sensitive mutations and have significantly improved prognosis. EGFR exon 19 deletions and L858R mutation in exon 21 are the most common sensitive mutations in lung adenocarci...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Inc.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6693705/ https://ncbi.nlm.nih.gov/pubmed/31064887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0732 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|